Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus type 5 vector vaccine
- Development stage
- Approved
- Lead developer
- CanSino Biologics
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Inhalation
01
Overview
The adenovirus type 5 vector vaccine, known by its brand name Convidecia, is a single-dose viral vector vaccine developed by CanSino Biologics for COVID-19. It utilizes a non-replicating human adenovirus type 5 (Ad5) as a vector to deliver genetic material encoding the SARS-CoV-2 spike protein into host cells. This process prompts the host cells to produce the spike protein, which then acts as an antigen, stimulating both humoral (antibody) and cellular immune responses against SARS-CoV-2. The vaccine has demonstrated efficacy in preventing moderate and severe cases of COVID-19 and can be stored at standard refrigerator temperatures (2°C to 8°C). It is administered intramuscularly, with an inhaled version, Convidecia Air, also available.
- Brand names
- Convidecia克威莎PakVacConvidecia Air
- Other names
- 重组新型冠状病毒疫苗（5型腺病毒载体）Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on adenovirus type 5 vector vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus type 5 vector vaccine.